How the answers frame Johnson & Johnson
This snapshot, taken on 2026-09-29, covers 250 benchmark questions across five assistants, or 1,250 answers. None of the questions named a brand. Johnson & Johnson was named in 192 of the answers, more than any other company in its healthcare and pharma peer set. Grok named it in 60 of 250 answers and Gemini in 41. Claude and Perplexity each named it in 31, and ChatGPT in 29. The 24 stored answers we read are a sample of those 192.
In those answers J&J is mostly one name in a list. It turns up in lists of oncology pipeline leaders, robotic surgery makers, big R&D spenders, free-drug programs for uninsured cancer patients, and engineering employers. The credit tags follow the same pattern: the largest group, 13, was classed as not substantive. Smaller groups were tagged Safety & Compliance (3), Financial Performance (2) and Sustainability & Ethics (1).
The same list-style presence extends to questions about controversy. J&J is named in answers about the opioid crisis, kickback settlements, whistleblower suits, product withdrawals and failed phase 3 trials. Claude's answer on failed trials described the milvexian study, run with Bristol Myers Squibb, as halted early. Gemini's kickbacks answer described a 2013 settlement over the marketing of Risperdal and other drugs.
By question intent, J&J's visibility was highest on leadership questions (42%) and questions framed around what to avoid (33%). It was 25% on sustainability and 20% on trust. It was near zero on value (0%) and service (1%), and low on reliability (6%). Across the sampled answers the company is placed in prestige lists and in scandal lists, and rarely in answers about everyday service or price.
Consistently ranked among the world's most admired healthcare companies, Johnson & Johnson is praised for its comprehensive approach to global health.
What the press is saying
The PeakMetrics news index recorded 15,472 mentions of J&J in the last 30 days, with the company in the headline of 1,918 of them. Several other peers drew more coverage in the same index, including Merck, Amgen, Eli Lilly and Pfizer.
The recent headlines sampled are mostly market and product items. Two are Kalkine Media pieces, one on J&J's place in a healthcare stocks discussion and one on its dividend streak. Another covers shares moving after insider selling, and another a CE marking for ACUVUE OASYS MAX 2-Week contact lenses. One headline, from brighteon.com, claims J&J knew of asbestos in baby powder since 1957.
J&J also became a major target in the litigation and public backlash.
The gap
The press sample leans toward stock commentary, dividends and a product approval, with one talc headline. None of the sampled answers dealt with talc. They centered on the opioid litigation, kickback settlements, failed trials and, on the favorable side, R&D, patient assistance and global health.
News volume and AI visibility do not track each other in this peer set. Amgen had a similar news count to Merck and Eli Lilly but was named in only 69 answers. J&J's news count was lower than several peers, yet it was named in more answers than any of them. The AI story for J&J is being written by lists and older reference material, and is not simply a reflection of this month's coverage.
A titan in the field, particularly strong in orthopedics, surgical robotics, and interventional solutions.
What to watch
First, the legacy questions. When an assistant is asked which companies have the worst reputations after the opioid crisis, or which were fined over kickbacks, J&J is a named example in the answers we read. ChatGPT tied it to the opioid litigation, and Claude's answer said it found no clear evidence of reputational recovery. The sources behind those answers are the place to look first.
Second, the thin credit. Most of J&J's mentions are inclusion in a list, not a specific reason attached to the name. Where an answer does give a reason, it is often a single line, so the company's own claims on pipeline and access programs are not yet a settled part of the answers.
Third, the near-zero showing on value and service questions. This is one snapshot of live answers, and the same questions can produce different names on another run. It is still a useful baseline for repeat benchmarking.